VITAMIN A (100,000 IU) AND VITAMIN E (20 IU) ORAL LIQUID PREPARATION CAPSULE

Ország: Kanada

Nyelv: angol

Forrás: Health Canada

Vedd Meg Most

Termékjellemzők Termékjellemzők (SPC)
08-04-2016

Aktív összetevők:

VITAMIN A (RETINYL PALMITATE); VITAMIN E (DL-ALPHA TOCOPHERYL ACETATE)

Beszerezhető a:

NUTRICORP INTERNATIONAL

ATC-kód:

A11JA

INN (nemzetközi neve):

COMBINATIONS OF VITAMINS

Adagolás:

100000UNIT; 20UNIT

Gyógyszerészeti forma:

CAPSULE

Összetétel:

VITAMIN A (RETINYL PALMITATE) 100000UNIT; VITAMIN E (DL-ALPHA TOCOPHERYL ACETATE) 20UNIT

Az alkalmazás módja:

ORAL

db csomag:

500

Recept típusa:

Prescription

Terápiás terület:

VITAMIN A

Termék összefoglaló:

Active ingredient group (AIG) number: 0225696006; AHFS:

Engedélyezési státusz:

APPROVED

Engedély dátuma:

2016-04-06

Termékjellemzők

                                _ _
_Page 1 of 34_
PRODUCT MONOGRAPH
PR
VITAMIN A (100,000 IU) AND VITAMIN E (20 IU) ORAL LIQUID PREPARATION
VITAMIN A AND VITAMIN E SOFTGEL CAPSULES
100,000 IU Vitamin A (all-trans-retinyl palmitate) and 20 IU Vitamin E
(all-rac-alpha-
tocopheryl acetate)
One IU of Vitamin A is equivalent to the activity of 0.3 mcg of
all-trans-retinol
ATC code: Vitamins – A11
Nutricorp International
4025 Rhodes Drive
Windsor, Ontario
N8W 5B5
Date of Preparation:
April 5, 2016
Submission Control No: 167923
_ _
_ _
_Page 2 of 34_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................4
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................5
DRUG INTERACTIONS
....................................................................................................6
DOSAGE AND ADMINISTRATION
................................................................................7
OVERDOSAGE
..................................................................................................................8
ACTION AND CLINICAL PHARMACOLOGY
..............................................................9
STORAGE AND STABILITY
..........................................................................................12
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................12
PART II: SCIENTIFIC INFORMATION
...............................................................................14
PHARMACEUTICAL INFORMATION
.......................................................
                                
                                Olvassa el a teljes dokumentumot
                                
                            

Dokumentumok más nyelveken

Termékjellemzők Termékjellemzők francia 22-02-2017